Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...

2023-05-08 19:30 1472

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease * Data presented shows preclinical proof of concept for HMBD-011 clearance of VH4-34+ antibodies and effective inhibition of col...

2023-05-08 18:30 1952

Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...

2023-05-08 16:50 2418

Transcenta to Present Two Clinical Trial Progress at ASCO 2023

SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...

2023-05-08 14:55 2009

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide...

2023-05-08 14:00 1530

EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives

TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A inEurope. Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show th...

2023-05-08 10:00 1991

Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-05-08 08:00 3108

Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine

ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-05-08 08:00 3788

BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic coll...

2023-05-08 07:00 2078

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Pha...

2023-05-08 05:00 5256

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injectio...

2023-05-08 05:00 2196

NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE

* Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST * QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in theINVICTUS Phase 3 Study1,2 ...

2023-05-08 04:00 1799

Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted

SUZHOU, China, May 6, 2023 /PRNewswire/ -- Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA. GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular...

2023-05-06 21:00 4598

Empowering Innovation to the Global Market with Acro Certify

NEWARK, Del., May 5, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. These obstacles can come in various forms. Sometimes the problem is finding the right target customer base or establishing an appropriate quality management system and shipping logist...

2023-05-06 10:18 4744

Empowering Innovation to the Global Market with Acro Certify

TOKYO, May 6, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. It is an immense logistical and financial challenge that makes or breaks a company, despite the product itself. For companies in that awkward, transitional stage from start-up company to a m...

2023-05-06 10:18 4243

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche'...

2023-05-05 20:50 3144

Viva Biotech's Recent Conferences & Events Review

HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...

2023-05-05 19:58 3712

ProQure and Identiv Partner to Launch Innovative NFC Type 2 Tags for Large-Scale NFC Deployments

The partnership's new PQ201/201s series tags deliver premium features at a competitive price point PLEASANTON, Calif., May 5, 2023 /PRNewswire/ -- ProQure, a technology provider of IoT cloud management for physical objects, and Identiv, a global leader in physical security and secure identificat...

2023-05-05 18:00 2248

P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'

* Dons the purple ribbon for the 2nd consecutive year to raise awareness on Peripheral Neuropathy, a condition significantly underdiagnosed and undertreated inAsia, Middle East & Africa * Releases new research study highlighting the role of B Vitamins in supporting healthy nerve functions SIN...

2023-05-05 11:30 3356

P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the pot...

2023-05-05 08:00 1771

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

1 ... 65 66 676869 70 71 ... 293